Evidence map›Paper›PMID 35740153›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Decreased Antibiotic Consumption Coincided with Reduction in Bacteremia Caused by Bacterial Species with Respiratory Transmission Potential during the COVID-19 Pandemic.

Vincent Chi-Chung Cheng, Shuk-Ching Wong, Simon Yung-Chun So, Jonathan Hon-Kwan Chen, Pui-Hing Chau, Albert Ka-Wing Au, Kelvin Hei-Yeung Chiu, Xin Li, Patrick Ip, Vivien Wai-Man Chuang and 9 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Clinical microbiology reviews · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Invasive group A streptococcal disease surveillance in Canada, 2021-2022.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024
    Article
  11. Post-COVID-19 Pandemic Rebound of Macrolide-ResistantAntibiotics (Basel, Switzerland) · 2024
    Article
  12. The Emergence ofInfection and drug resistance · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Gastrointestinal Colonization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  20. Control of Healthcare-Associated Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Vincent Chi-Chung ChengInfection Control Team, Queen Mary Hospital, Hong Kong West Cluster, Hong Kong, China.ORCID 0000-0003-1765-7706
Shuk-Ching WongInfection Control Team, Queen Mary Hospital, Hong Kong West Cluster, Hong Kong, China.ORCID 0000-0001-6101-1932
Simon Yung-Chun SoDepartment of Microbiology, Queen Mary Hospital, Hong Kong, China.
Jonathan Hon-Kwan ChenDepartment of Microbiology, Queen Mary Hospital, Hong Kong, China.
Pui-Hing ChauSchool of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID 0000-0003-0287-8020
Albert Ka-Wing AuCentre for Health Protection, Department of Health, Hong Kong, China.
Kelvin Hei-Yeung ChiuDepartment of Microbiology, Queen Mary Hospital, Hong Kong, China.
Xin LiDepartment of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Patrick IpDepartment of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID 0000-0002-6797-6898
Vivien Wai-Man ChuangQuality & Safety Division, Hospital Authority, Hong Kong, China.
David Christopher LungDepartment of Pathology, Queen Elizabeth Hospital, Hong Kong, China.
Cindy Wing-Sze TseDepartment of Pathology, Kwong Wah Hospital, Hong Kong, China.
Rodney Allan LeeDepartment of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Kitty Sau-Chun FungDepartment of Pathology, United Christian Hospital, Hong Kong, China.
Wing-Kin ToDepartment of Pathology, Princess Margaret Hospital, Hong Kong, China.
Raymond Wai-Man LaiQuality & Safety Division, Hospital Authority, Hong Kong, China.
Tak-Lun QueDepartment of Pathology, Tuen Mun Hospital, Hong Kong, China.
Janice Yee-Chi LoCentre for Health Protection, Department of Health, Hong Kong, China.
Kwok-Yung YuenDepartment of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Queen Mary Hospital · CNUniversity of Hong Kong · HKDepartment of Health · CNHospital Authority · HKKwong Wah Hospital · CNPamela Youde Nethersole Eastern Hospital · CNQueen Elizabeth Hospital · CNTuen Mun Hospital · CNUnited Christian Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonpharmaceutical interventions implemented during the COVID-19 pandemic (2020−2021) have provided a unique opportunity to understand their impact on the wholesale supply of antibiotics and incidences of infections represented by bacteremia due to common bacterial species in Hong Kong. The wholesale antibiotic supply data (surrogate indicator of antibiotic consumption) and notifications of scarlet fever, chickenpox, and tuberculosis collected by the Centre for Health Protection, and the data of blood cultures of patients admitted to public hospitals in Hong Kong collected by the Hospital Authority for the last 10 years, were tabulated and analyzed. A reduction in the wholesale supply of antibiotics was observed. This decrease coincided with a significant reduction in the incidence of community-onset bacteremia due to Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, which are encapsulated bacteria with respiratory transmission potential. This reduction was sustained during two pandemic years (period 2: 2020−2021), compared with eight pre-pandemic years (period 1: 2012−2019). Although the mean number of patient admissions per year (1,704,079 vs. 1,702,484, p = 0.985) and blood culture requests per 1000 patient admissions (149.0 vs. 158.3, p = 0.132) were not significantly different between periods 1 and 2, a significant reduction in community-onset bacteremia due to encapsulated bacteria was observed in terms of the mean number of episodes per year (257 vs. 58, p < 0.001), episodes per 100,000 admissions (15.1 vs. 3.4, p < 0.001), and per 10,000 blood culture requests (10.1 vs. 2.1, p < 0.001), out of 17,037,598 episodes of patient admissions with 2,570,164 blood culture requests. Consistent with the findings of bacteremia, a reduction in case notification of scarlet fever and airborne infections, including tuberculosis and chickenpox, was also observed; however, there was no reduction in the incidence of hospital-onset bacteremia due to Staphylococcus aureus or Escherichia coli. Sustained implementation of non-pharmaceutical interventions against respiratory microbes may reduce the overall consumption of antibiotics, which may have a consequential impact on antimicrobial resistance. Rebound of conventional respiratory microbial infections is likely with the relaxation of these interventions.

Indexed as

antibiotic consumptionbacteremiaCOVID-19transmission

Identifiers

PMID35740153
PMCPMC9219721
OpenAlexW4281681432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.